8-K: Candel Therapeutics Unveils Strong Clinical Data, BLA Path

Candel Therapeutics presented positive clinical trial results for its lead immunotherapy candidates, CAN-2409 and CAN-3110, outlining a clear path to regulatory submission and commercialization.

Summary

• Candel Therapeutics hosted a virtual Research and Development (R&D) Day on December 5, 2025, providing an extensive overview of its viral immunotherapy approach and oncology-focused pipeline.
• CAN-2409, an off-the-shelf pan-solid tumor therapy, showed positive Phase 3 randomized placebo-controlled clinical trial results in localized, intermediateto high-risk prostate cancer, demonstrating a 30% risk reduction in disease recurrence (P=0.0155) and a 38% reduction in prostate cancer-specific DFS (P=0.0046).
• CAN-2409 also demonstrated positive overall survival data from a randomized Phase 2a clinical trial in immune checkpoint inhibitor (ICI) refractory non-small cell lung cancer (NSCLC), with a median overall survival (mOS) of 24.5 months, significantly exceeding historical controls of 9.8-11.8 months for standard of care chemotherapy.
• CAN-3110, an oncolytic HSV-1, showed proof of concept in patients with recurrent high-grade glioma (rHGG), with monotherapy treatment associated with a doubling of expected median overall survival (<6-9 months historical) and durable responses.
• The company reported cash and cash equivalents of $87.0 million as of September 30, 2025, with an expected cash runway into Q1 2027.
• A term loan facility of up to $130 million was entered into in October 2025.
• CAN-2409 has FDA Regenerative Medicine Advanced Therapy (RMAT) designation in prostate cancer, and Fast Track designation in NSCLC, pancreatic cancer, and prostate cancer, along with Orphan Drug designation in pancreatic cancer.
• CAN-3110 has Fast Track designation and Orphan Drug designation in rHGG.
• A Biologics License Application (BLA) for CAN-2409 in prostate cancer is on track for submission to the FDA in Q4 2026, eligible for Priority Review, Expedited Review, and Rolling Review.
• Pre-commercialization activities for CAN-2409 in prostate cancer are underway, with physician feedback indicating high interest and potential for strong uptake.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive clinical trial results for both lead candidates, CAN-2409 and CAN-3110, significantly exceeding historical benchmarks in challenging oncology indications. The clear regulatory pathway with BLA submission planned for Q4 2026, strong financial runway, and active pre-commercialization efforts indicate robust progress and strategic execution. The high physician interest and favorable payer reception further bolster a very positive outlook.

Positives

• CAN-2409 achieved a statistically significant 30% reduction in disease recurrence (DFS) in its Phase 3 prostate cancer trial (HR 0.70, P=0.0155).
• CAN-2409 showed a 38% reduction in prostate cancer-specific DFS (HR 0.62, P=0.0046).
• CAN-2409 demonstrated a significant increase in PSA nadir <0.2 ng/mL (67.1% vs 58.6%, P=0.0164) and pathological complete response (80.4% vs 63.6%, P=0.0015) in prostate cancer.
• The safety profile for CAN-2409 in prostate cancer was compelling, with lower incidence of serious adverse events (5.8% vs 7.3%) and treatment-related SAEs (1.7% vs 2.2%) in the active arm.
• CAN-2409 achieved a median overall survival (mOS) of 24.5 months in ICI-refractory NSCLC patients, significantly outperforming historical controls (9.8-11.8 months).
• A 'long tail of survival' was observed in NSCLC, with 37% of patients alive >2 years after CAN-2409 administration.
• CAN-3110 monotherapy in recurrent high-grade glioma doubled the expected median overall survival (<6-9 months historical) and showed durable responses.
• The company has a strong cash position of $87.0 million as of September 30, 2025, providing a runway into Q1 2027.
• A new term loan facility of up to $130 million was secured in October 2025, enhancing financial flexibility.
• CAN-2409 and CAN-3110 hold multiple FDA designations, including RMAT, Fast Track, and Orphan Drug, indicating regulatory support and potential for expedited review.
• Pre-commercialization activities for CAN-2409 are well underway, with strong physician interest and anticipated high uptake rates (e.g., 72% in unfavorable intermediate-risk prostate cancer).
• The company has robust IP protection for CAN-2409 (method of use until 2034) and CAN-3110 (composition of matter until 2036), plus 12 years of data exclusivity.

Negatives

• No specific negative results or outcomes were highlighted in the filing; the presentation focused on positive clinical data and future plans.

Risks

• The initiation, timing, progress, results, and cost of research and development programs and current and future preclinical and clinical studies may not align with projections.
• The therapeutic benefit of programs, including the potential for product candidates to extend patient survival, may not be realized as expected.
• The ability to efficiently discover and develop product candidates is subject to uncertainties.
• The company may not be able to initiate, recruit and enroll patients in, and conduct clinical trials at the projected pace.
• Obtaining and maintaining regulatory approval for product candidates is not guaranteed.
• The company faces competition from other companies marketing or developing treatments for the same target indications.
• Reliance on third parties to conduct clinical trials and manufacture drug substance introduces risks.
• The size and growth potential of the markets for product candidates and the company's ability to serve those markets may differ from estimates.
• Third-party strategic collaborators may not continue research and development activities relating to development candidates and product candidates.
• The ability to obtain and maintain adequate intellectual property rights is crucial and subject to challenges.
• Estimates of future expenses, revenue, capital requirements, or the need for or ability to obtain additional financing may prove incorrect.
• The company's ability to continue as a going concern is subject to various factors.
• The potential benefits of strategic collaboration agreements, and the ability to enter into additional collaborations, may not materialize.
• Financial performance is subject to various market and operational risks.
• Developments and projections relating to competitors or the industry could negatively impact the company.
• Information based on estimates, projections, and third-party sources has not been independently verified, and there is no guarantee as to the accuracy or reliability of assumptions or internal research.

Future Outlook

Candel Therapeutics anticipates filing a Biologics License Application (BLA) for CAN-2409 in prostate cancer with the FDA in Q4 2026, with eligibility for Priority, Expedited, and Rolling Review. The company is also conducting pre-commercialization activities to support a potential post-approval commercial launch of CAN-2409. Further clinical data updates for CAN-2409 in prostate cancer and NSCLC, as well as biomarker data for CAN-3110 in recurrent high-grade glioma, are expected in 2025-2026. The company projects its cash runway to extend into Q1 2027.

Management Comments

• Management believes that the expectations reflected in forward-looking statements are reasonable, but acknowledges known and unknown risks.
• The BLA strategy is on track for submission to FDA in Q4 2026, with eligibility for Priority, Expedited, and Rolling Review.
• FDA has aligned with the company's approach to setting RCA specification, proposed nonclinical toxicology package, clinical biodistribution/shedding study, and analytical approach for comparability.
• The primary evidence from the proposed phase 3 registrational study for CAN-2409 in NSCLC, if successful and supported by confirmatory phase 2 data, could demonstrate substantial evidence of effectiveness (SEE) to support a supplemental BLA submission.
• The company's commercial strategy is anchored in establishing stakeholder belief in CAN-2409, optimizing distribution, and maximizing pricing by communicating strong value.

Industry Context

Candel Therapeutics operates in the highly competitive and innovative immuno-oncology space, focusing on viral immunotherapy. Its approach to leveraging the immune system to fight solid tumors, particularly with 'off-the-shelf' therapies like CAN-2409 and tumor-specific replication viruses like CAN-3110, aligns with a major trend in cancer treatment. The positive clinical results, especially the significant overall survival benefits observed in ICI-refractory NSCLC and recurrent glioblastoma, position Candel as a potential leader in addressing high unmet needs in these challenging indications. The pre-commercialization efforts and BLA roadmap for prostate cancer indicate a strategic move to capitalize on its pipeline advancements and enter the market with novel therapeutic options.

Comparison to Industry Standards

• CAN-2409's median overall survival (mOS) of 24.5 months in ICI-refractory NSCLC patients (per-protocol) markedly exceeds historical controls for standard of care chemotherapy, which typically range from 9.8 to 11.8 months (e.g., EVOKE-01 Trial, TROPION-LUNG01 Trial).
• For nonsquamous NSCLC patients with progressive disease despite ICI, CAN-2409 achieved an mOS of 25.4 months (per-protocol), compared to historical controls of 9.9-12.3 months for SoC chemo.
• CAN-3110 monotherapy in recurrent high-grade glioma (glioblastoma) is associated with a doubling of expected median overall survival, which is historically less than 6-9 months.
• The illustrative pricing range for CAN-2409 in localized prostate cancer ($140k-$190k annual WAC) is considered by payers to be in line with annualized costs of other prostate cancer therapies, suggesting competitive positioning against existing treatments like novel cell-based immunotherapies, microtubule inhibitors, PSMA-targeted radioligands, PARP inhibitors, and antiandrogens (some of which have WACs up to ~$290k).

Stakeholder Impact

• **Shareholders:** Positive clinical trial results and a clear path to market for lead candidates could significantly increase shareholder value. The extended cash runway and new loan facility reduce immediate dilution concerns.
• **Patients:** The development of CAN-2409 and CAN-3110 offers potential new, more effective treatment options for patients with localized prostate cancer, ICI-refractory NSCLC, and recurrent high-grade glioma, addressing significant unmet medical needs.
• **Healthcare Providers (HCPs):** Physicians (urologists, radiation oncologists, medical oncologists) expressed high interest and excitement in CAN-2409, indicating potential for adoption as a new standard of care, which could improve patient outcomes.
• **Payers:** Payers are receptive to the pricing of CAN-2409, especially if included in NCCN guidelines, suggesting potential for broad coverage and access.
• **Employees:** Continued progress in clinical development and commercialization efforts provides job security and potential for growth within the company.

Next Steps

• BLA filing for CAN-2409 in prostate cancer with the FDA in Q4 2026.
• Continued pre-commercialization activities to support potential post-approval commercial launch of CAN-2409.
• Updated overall survival (OS) data for CAN-2409 in prostate cancer and NSCLC.
• New recurrent high-grade glioma (HGG) biomarker data for CAN-3110.
• Initiation of Phase 3 clinical trial for CAN-2409.
• Phase 1b (Arm C) for CAN-3110.
• Ongoing conduct of planned nonclinical studies and BLA module preparations.
• Continued interactions with FDA regarding BLA submission and comparability.

Key Dates

Recommendation

The filing reveals exceptionally strong clinical data for Candel Therapeutics' lead assets, CAN-2409 and CAN-3110, across multiple high-unmet-need oncology indications. CAN-2409's Phase 3 success in prostate cancer with a 30% DFS reduction and its significant OS benefit in ICI-refractory NSCLC (24.5 months vs. 9.8-11.8 months historical) are transformative. CAN-3110's doubling of mOS in recurrent glioblastoma is also highly compelling. The company has a clear regulatory path with a BLA submission for CAN-2409 in Q4 2026, supported by FDA designations and ongoing pre-commercialization activities. Financially, the extended cash runway into Q1 2027 and the new $130 million term loan provide stability. The high physician interest and favorable payer reception suggest strong market potential. These factors collectively indicate a robust investment opportunity with significant upside potential.

Keywords

Candel Therapeutics, CAN-2409, CAN-3110, Immunotherapy, Oncology, Prostate Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Viral Immunotherapy, Clinical Trials, Phase 3, Phase 2a, FDA RMAT, Fast Track, Orphan Drug, Biologics License Application, BLA, Cancer Treatment, Oncolytic Virus, Drug Development, Biotechnology, Pharmaceuticals